Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) has been given an average recommendation of "Hold" by the seven research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $29.6667.
A number of analysts have issued reports on UPB shares. Weiss Ratings raised Upstream Bio from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Monday, August 17th. JPMorgan Chase & Co. increased their target price on Upstream Bio from $8.00 to $9.00 and gave the company a "neutral" rating in a research report on Friday, August 14th. Wall Street Zen cut shares of Upstream Bio from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. Truist Financial reduced their price target on shares of Upstream Bio to $25.00 and set a "buy" rating on the stock in a research report on Tuesday, August 11th. Finally, Mizuho decreased their price target on shares of Upstream Bio from $51.00 to $50.00 and set an "outperform" rating on the stock in a research note on Thursday, May 14th.
Check Out Our Latest Report on UPB
Upstream Bio Stock Down 5.2%
Shares of Upstream Bio stock opened at $6.61 on Tuesday. Upstream Bio has a twelve month low of $5.85 and a twelve month high of $33.68. The business has a 50-day moving average price of $6.88 and a 200-day moving average price of $8.74. The firm has a market cap of $362.04 million, a price-to-earnings ratio of -2.28 and a beta of 1.26.
Upstream Bio (NASDAQ:UPB - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.73) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.01. Upstream Bio had a negative return on equity of 48.40% and a negative net margin of 4,955.67%.The company had revenue of $0.77 million for the quarter, compared to the consensus estimate of $0.56 million. On average, equities analysts expect that Upstream Bio will post -2.86 EPS for the current fiscal year.
Institutional Investors Weigh In On Upstream Bio
Several large investors have recently added to or reduced their stakes in UPB. Torren Management LLC purchased a new stake in Upstream Bio during the fourth quarter valued at approximately $30,000. Empowered Funds LLC purchased a new position in shares of Upstream Bio in the 4th quarter worth approximately $45,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Upstream Bio during the 4th quarter valued at approximately $71,000. Russell Investments Group Ltd. increased its position in shares of Upstream Bio by 1,963.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company's stock valued at $57,000 after purchasing an additional 2,887 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of Upstream Bio by 229.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company's stock valued at $34,000 after purchasing an additional 2,158 shares during the last quarter.
About Upstream Bio
(
Get Free Report)
Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio's approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.
The company's research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
